The lack of ARID1A has been associated with a higher presence of CD8+ tumor-infiltrating lymphocytes (TILs) and intratumoral CD8+ immune cells in EAOC, suggesting the potential effectiveness of targeted immunotherapy in this specific context (17). This evidence concerns the gene ARID1A and neoplasm.